Literature DB >> 2341907

Reduction-mediated technetium-99m labeling of monoclonal antibodies.

S J Mather1, D Ellison.   

Abstract

A simple and generally applicable method for labeling antibodies with technetium-99m (99mTc) is described. Following reduction of intrinsic disulphide bonds, the antibody is labeled with 99mTc in the presence of a weak competing ligand methylene diphosphonate. High labeling efficiencies (greater than 97%), in a final labeling step taking only a few minutes, can be routinely obtained with high in-vitro stability over 24 hr. No effect upon antibody reactivity is seen.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2341907

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  32 in total

1.  Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment:a radioimmunoconjugate for hepatocellular carcinoma imaging.

Authors:  Hui-Jie Bian; Zhi-Nan Chen; Jing-Lan Deng
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 2.  The development of new radiopharmaceuticals.

Authors:  K E Britton
Journal:  Eur J Nucl Med       Date:  1990

3.  Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m.

Authors:  M A Stalteri; S J Mather; B A Belinka; D J Coughlin; V U Chengazi; K E Britton
Journal:  Eur J Nucl Med       Date:  1997-06

4.  Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.

Authors:  M A Stalteri; S J Mather
Journal:  Eur J Nucl Med       Date:  1996-02

5.  Radioimmunolocalization of human pancreatic carcinoma xenograft by 99mTc-labeled YPC3 monoclonal antibody.

Authors:  Q Chen; S Yuan
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.

Authors:  Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

7.  A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer.

Authors:  H Kobayashi; H Sakahara; T Saga; M Hosono; M Shirato; H Kanda; K Ishibashi; T Watanabe; K Endo; I Ishiwata
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

8.  Technetium-99m labelling of human immunoglobulin and preliminary clinical evaluation in tumour patients.

Authors:  A D Varvarigou; S C Archimandritis; A Stripsanelli; A Arka; P Kostamis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

9.  Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer.

Authors:  M Granowska; K E Britton; S J Mather; G Morris; D Ellison; S Soobramoney; I C Talbot; J M Northover
Journal:  Eur J Nucl Med       Date:  1993-08

10.  Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.

Authors:  N Watanabe; N Oriuchi; S Sugiyama; M Kuroki; Y Matsuoka
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.